Dimerix, a drug discovery company, has announced a manufacturing schedule to start later this month for its extended release tablet of propagermanium, which will be used in the DMX-200 human PK study and Phase IIb trial in chronic kidney disease
Original Article: Extended-release tablet manufacture and study announced by Dimerix
NEXT ARTICLESource: Extended-release tablet manufacture and study announced by Dimerix
No comments:
Post a Comment